BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $4578.T readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07173478-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~OPA-15406 readout (P3) · Otsuka Pharmaceutical Co.\, Ltd. $4578.T
DESCRIPTION:A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 
 Foam to the Vehicle in Adult Patients With Atopic Dermatitis\n\nPrimary co
 mpletion date: 2026-12 (estimated) — month only\, shown on the 1st\nPhas
 e 3 · Immuno · Atopic Dermatitis (AD)\nEnrollment: 156 · Sites: 1\n\nPr
 imary completion = last participant's primary-endpoint data collected\; to
 pline results usually follow weeks to months later. Sponsor-reported\, oft
 en an estimate. Not investment advice.\n\nhttps://datacutoff.com/r
 adar.html?nct=NCT07173478\nhttps://clinicaltrials.gov/study/NCT07173478
URL:https://datacutoff.com/radar.html?nct=NCT07173478
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07184645-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:~OPA-15406 readout (P3) · Otsuka Pharmaceutical Co.\, Ltd. $4578.T
DESCRIPTION:A Phase 3 Trial of OPA-15406 Foam in Children and Infants With 
 Atopic Dermatitis\n\nPrimary completion date: 2027-02 (estimated) — mont
 h only\, shown on the 1st\nPhase 3 · Immuno · Atopic Dermatitis (AD)\nEn
 rollment: 198 · Sites: 1\n\nPrimary completion = last participant's prima
 ry-endpoint data collected\; topline results usually follow weeks to month
 s later. Sponsor-reported\, often an estimate. Not investment advice.\n\nh
 ttps://trialsonar.netlify.app/radar.html?nct=NCT07184645\nhttps://clinical
 trials.gov/study/NCT07184645
URL:https://datacutoff.com/radar.html?nct=NCT07184645
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06928142-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270313
DTEND;VALUE=DATE:20270314
SUMMARY:EnVISage readout (P2) · Otsuka Pharmaceutical Development & Commer
 cialization\, Inc. $4578.T
DESCRIPTION:A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Ad
 ministered Subcutaneously in Participants With Sjögren's\n\nPrimary compl
 etion date: 2027-03-13 (estimated)\nPhase 2 · Immuno · Sjogren Disease\n
 Enrollment: 83 · Sites: 63\n\nPrimary completion = last participant's pri
 mary-endpoint data collected\; topline results usually follow weeks to mon
 ths later. Sponsor-reported\, often an estimate. Not investment advice.\n\
 nhttps://datacutoff.com/radar.html?nct=NCT06928142\nhttps://clinic
 altrials.gov/study/NCT06928142
URL:https://datacutoff.com/radar.html?nct=NCT06928142
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07759154-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270527
DTEND;VALUE=DATE:20270528
SUMMARY:Centanafadine XR readout (P3) · Otsuka Pharmaceutical Development 
 & Commercialization\, Inc. $4578.T
DESCRIPTION:A Study to Test the Effects of Centanafadine in Adults With Att
 ention-deficit/Hyperactivity Disorder and Emotional Dysregulation\n\nPrima
 ry completion date: 2027-05-27 (estimated)\nPhase 3 · Neuro · Attention-
 deficit/Hyperactivity Disorder\, Emotional Dysregulation\nEnrollment: 80 
 · Sites: 16\n\nPrimary completion = last participant's primary-endpoint d
 ata collected\; topline results usually follow weeks to months later. Spon
 sor-reported\, often an estimate. Not investment advice.\n\nhttps://trials
 onar.netlify.app/radar.html?nct=NCT07759154\nhttps://clinicaltrials.gov/st
 udy/NCT07759154
URL:https://datacutoff.com/radar.html?nct=NCT07759154
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07086313-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:~EB-1020 (Centanafadine) low dose readout (P2/3) · Otsuka Pharmace
 utical Co.\, Ltd. $4578.T
DESCRIPTION:A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pedia
 tric Patients With ADHD\n\nPrimary completion date: 2027-08 (estimated) 
 — month only\, shown on the 1st\nPhase 2/3 · Neuro · Attention-Deficit
  Hyperactivity Disorder(ADHD)\nEnrollment: 315 · Sites: 1\n\nPrimary comp
 letion = last participant's primary-endpoint data collected\; topline resu
 lts usually follow weeks to months later. Sponsor-reported\, often an esti
 mate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?
 nct=NCT07086313\nhttps://clinicaltrials.gov/study/NCT07086313
URL:https://datacutoff.com/radar.html?nct=NCT07086313
CATEGORIES:Neuro,Phase 2/3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07087327-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:~EB-1020 (Centanafadine) low dose readout (P3) · Otsuka Pharmaceut
 ical Co.\, Ltd. $4578.T
DESCRIPTION:A Long-term Trial of EB-1020 in Pediatric Patients With ADHD\n\
 nPrimary completion date: 2027-08 (estimated) — month only\, shown on th
 e 1st\nPhase 3 · Neuro · Attention-Deficit Hyperactivity Disorder(ADHD)\
 nEnrollment: 180 · Sites: 1\n\nPrimary completion = last participant's pr
 imary-endpoint data collected\; topline results usually follow weeks to mo
 nths later. Sponsor-reported\, often an estimate. Not investment advice.\n
 \nhttps://datacutoff.com/radar.html?nct=NCT07087327\nhttps://clini
 caltrials.gov/study/NCT07087327
URL:https://datacutoff.com/radar.html?nct=NCT07087327
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05325645-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~OPC-34712FUM/ Brexpiprazole fumarate readout (P3) · Otsuka Pharma
 ceutical Co.\, Ltd. $4578.T
DESCRIPTION:Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients
  With Acute Schizophrenia\n\nPrimary completion date: 2027-09 (estimated) 
 — month only\, shown on the 1st\nOriginally planned: 2025-04 (+29.0 mont
 hs)\nPhase 3 · Neuro · Acute Schizophrenia\nEnrollment: 450 · Sites: 1\
 n\nPrimary completion = last participant's primary-endpoint data collected
 \; topline results usually follow weeks to months later. Sponsor-reported\
 , often an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.
 app/radar.html?nct=NCT05325645\nhttps://clinicaltrials.gov/study/NCT053256
 45
URL:https://datacutoff.com/radar.html?nct=NCT05325645
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06628128-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:JNT-517 readout (P3) · Otsuka Pharmaceutical Development & Commerc
 ialization\, Inc. $4578.T
DESCRIPTION:A Long-Term Study of JNT-517 in Participants With Phenylketonur
 ia\n\nPrimary completion date: 2027-11-01 (estimated)\nPhase 3 · Rare · 
 Phenylketonuria (PKU)\nEnrollment: 240 · Sites: 12\n\nPrimary completion 
 = last participant's primary-endpoint data collected\; topline results usu
 ally follow weeks to months later. Sponsor-reported\, often an estimate. N
 ot investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT
 06628128\nhttps://clinicaltrials.gov/study/NCT06628128
URL:https://datacutoff.com/radar.html?nct=NCT06628128
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
